期刊文献+

奥沙利铂联合卡培他滨治疗中老年晚期结肠癌患者的效果观察 被引量:2

下载PDF
导出
摘要 目的对中老年晚期结肠癌患者采用奥沙利铂联合卡培他滨治疗的效果进行观察。方法以我院中老年晚期结肠癌患者308例为研究对象,选取时间为2015年9月到2017年9月之间。采用数字随机抽取法将患者分为两组,每组154例。使用奥沙利铂治疗对照组患者,采用奥沙利铂联合卡培他滨治疗观察组患者,将两组的治疗效果进行比较。结果观察组的总有效率为92.86%。显著高于对照组的77.92%,差异有统计学意义(P<0.05)。结论对于中老年晚期结肠癌患者,采用奥沙利铂联合卡培他滨治疗效果优异,且安全性高,适合在临床上推广使用。
作者 李世凤
出处 《海峡药学》 2019年第1期131-132,共2页 Strait Pharmaceutical Journal
  • 相关文献

参考文献4

二级参考文献27

  • 1张淼,陈克敏,赵泽华,凌华威.多层螺旋CT扫描在结肠癌术前分期中的应用[J].中华放射学杂志,2005,39(5):505-509. 被引量:64
  • 2Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in incidence, mortality, survival and prevalence in 2010[J]. Research and Treatment, 2013, 45(1): 1-14.
  • 3Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, Korea: Cancer 2014[J].CA, 2014, 64(2): 104-117.
  • 4Demes M, Seheil-Bertram S, Bartseh H, et al. Signature of mi- erosatellite instability, KRAS and BRAF gene mutations in Ger- man patients with locally advanced rectal adenoeareinoma before and after neoadjuvant 5-FU radioehemotherapy[J]. Journal of Gastrointestinal Oneology, 2013, 4(2): 182-192.
  • 5Southward K, Hutehins G, Handley K, et al. K-ras mutation is a negative prognostic marker, and does not preclude benefit from 5-fu in stage l]/m eoloreetal cancer[C]. Journal of Pathology, 2011, 224: $4.
  • 6National Cancer Institute. Common Terminology Criteria for Ad- verse Events (CTCAE) Version 4.02[S/OL]. (2009-09-15) [2011- 12-30].
  • 7Schubbert S, Shannon K, Bollag G. Hyperactive ras in develop mental disorders and cancer[J]. Nature Reviews Cancer, 2007, 7(4): 295-308.
  • 8Etienne-Grimaldi MC, Formento JL, Franeoual M, et al. K-Ras mutations and treatment outcome in eolorectal cancer patients re- ceiving exclusive fluoropyrimidine therapy[J]. Clinical Cancer Re- search, 2008, 14(15): 4830-4835.
  • 9Carsten B, Igor B, Anatoly M, et al. Fluorouracil, leucovorin, and oxaliplatin with and without eetuximab in the first-line treatment of metastatic eoloreetal cancer[J]. Journal of Clinical Ontology, 2009, 27(5): 663-671.
  • 10Li M, Liang Z, Sun X, et al. A polymeric prodrug of 5-fluo- rouracil-l-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrier[J]. PLoS One, 2014, 9(11): e112888.

共引文献55

同被引文献20

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部